Strömqvist M, Karlsson K E, Björquist P, Andersson J O, Byström M, Hansson L, Johansson T, Deinum J
Astra Hässle AB, Umeå, Sweden.
Biochim Biophys Acta. 1996 Jun 7;1295(1):103-9. doi: 10.1016/0167-4838(96)00035-0.
Glycosylated human plasminogen activator inhibitor type 1 (PAI-1), produced in Chinese hamster ovary (CHO) cells, showed a variety of compounds with different molecular weights when subjected to electrospray mass spectrometry (ES-MS), owing to the heterogeneity of the carbohydrate chains. However, non-glycosylated human PAI-1, produced in E. coli, gave rise to a prominent species with a molecular weight of 42,774, consistent with the amino-acid sequence. A non-glycosylated mutant of the proteinase domain (B-chain) of tissue-type plasminogen activator (tPA) produced in C 127 cells, had a molecular weight of 28,168. Full-length, glycosylated, tPA showed a large heterogeneity in molecular mass. For a mass study, a tPA-PAI-1 complex was formed, composed of non-glycosylated PAI-1 and non-glycosylated B-chain. This complex was remarkably stable at room temperature in buffer with a neutral pH. The mass spectrum of the complex provided two main species, a peptide with a mass of 3803 and a dominating species of 67,133. These masses are consistent with a complex where PAI-1 is cleaved at the P1-P1' position. A trace of a species with a molecular mass of 70,942 was also found, corresponding to the complete, non-dissociated complex with PAI-1. Separation of the cleaved peptide, corresponding to the hydrophobic C-terminal 33 amino-acid residues of PAI-1, from the complex, was achieved by size-exclusion chromatography in the presence of 30% acetonitrile. Thus, in the complex between tPA and PAI-1, the proteins are held together by a tight covalent bond, but the C-terminal cleaved peptide of PAI-1 is only bound to the complex by hydrophobic forces. To assess whether this is specific to the tPA B-chain alone, experiments with the complex of full-length, glycosylated tPA and glycosylated PAI-1 were also performed, and it was possible to demonstrate the release of the C-terminal PAI-1 peptide by chromatography, mass spectrometry, as well as by SDS-PAGE.
在中国仓鼠卵巢(CHO)细胞中产生的糖基化人纤溶酶原激活物抑制剂1型(PAI-1),由于糖链的异质性,在进行电喷雾质谱(ES-MS)分析时显示出多种不同分子量的化合物。然而,在大肠杆菌中产生的非糖基化人PAI-1产生了一种分子量为42,774的主要物质,这与氨基酸序列一致。在C127细胞中产生的组织型纤溶酶原激活物(tPA)蛋白酶结构域(B链)的非糖基化突变体的分子量为28,168。全长糖基化tPA在分子量上表现出很大的异质性。为了进行质量研究,形成了一种由非糖基化PAI-1和非糖基化B链组成的tPA-PAI-1复合物。该复合物在室温下于中性pH缓冲液中非常稳定。该复合物的质谱提供了两种主要物质,一种质量为3803的肽和一种占主导地位的质量为67,133的物质。这些质量与PAI-1在P1-P1'位置被切割的复合物一致。还发现了微量分子量为70,942的物质,对应于与PAI-1完全未解离的复合物。通过在30%乙腈存在下的尺寸排阻色谱法,从复合物中分离出对应于PAI-1疏水C末端33个氨基酸残基的切割肽。因此,在tPA和PAI-1之间的复合物中,蛋白质通过紧密的共价键结合在一起,但PAI-1的C末端切割肽仅通过疏水作用力与复合物结合。为了评估这是否仅对tPA B链具有特异性,还进行了全长糖基化tPA和糖基化PAI-1复合物的实验,并且可以通过色谱法、质谱法以及SDS-PAGE证明C末端PAI-1肽的释放。